CAR T-Cell Therapy for the Management of Multiple Myeloma

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.